Activation of p53-dependent responses in tumor cells treated with a PARC-interacting peptide

Biochemical and Biophysical Research Communications

Volumn 368, Issue 2, 2008, Pages 350-356

  Vitali, Roberta ^a   Cesi, Vincenzo ^a   Tanno, Barbara ^a   Ferrari Amorotti, Giovanna ^b   Dominici, Carlo ^c,d,e   Calabretta, Bruno ^b,f   Raschellà, Giuseppe ^a  

^a ENEA C R CASACCIA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Apoptosis; Etoposide; p53; PARC; TAT

Indexed keywords

CASPASE; DOXORUBICIN; ETOPOSIDE; PROTEIN P53; PROTEIN PARC; TRANSACTIVATOR PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; DNA BINDING; FLOW CYTOMETRY; GENE EXPRESSION; GENOTOXICITY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; TWO HYBRID SYSTEM; WESTERN BLOTTING; WILD TYPE;

APOPTOSIS; CELL LINE, TUMOR; DNA TOPOISOMERASE IV; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 39549119777     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.01.093     Document Type: Article

References (21)

1. Soussi T., Kato S., Levy P.P., and Ishioka C. Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations. Hum. Mutat. 25 (2005) 6-17
2. Moll U.M., LaQuaglia M., Benard J., and Riou G. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc. Natl. Acad. Sci. USA 92 (1995) 4407-4411
3. Nikolaev A.Y., Li M., Puskas N., Qin J., and Gu W. PARC: a cytoplasmic anchor for p53. Cell 112 (2003) 29-40
4. Kasper J.S., Arai T., and DeCaprio J.A. A novel p53-binding domain in CUL7. Biochem. Biophys. Res. Commun. 348 (2006) 132-138
5. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., Fotouhi N., and Liu E.A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303 (2004) 844-848
6. Hupp T.R., Sparks A., and Lane D.P. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 83 (1995) 237-245
7. Snyder E.L., Meade B.R., Saenz C.C., and Dowdy S.F. Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide. PLoS Biol. 2 (2004) E36
8. Ho A., Schwarze S.R., Mermelstein S.J., Waksman G., and Dowdy S.F. Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo. Cancer Res. 61 (2001) 474-477
9. Caron N.J., Torrente Y., Camirand G., Bujold M., Chapdelaine P., Leriche K., Bresolin N., and Tremblay J.P. Intracellular delivery of a Tat-eGFP fusion protein into muscle cells. Mol. Ther. 3 (2001) 310-318
10. Tanno B., Mancini C., Vitali R., Mancuso M., McDowell H.P., Dominici C., and Raschella G. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo. Clin. Cancer Res. 12 (2006) 6772-6780
11. Skorski T., Bellacosa A., Nieborowska-Skorska M., Majewski M., Martinez R., Choi J.K., Trotta R., Wlodarski P., Perrotti D., Chan T.O., Wasik M.A., Tsichlis P.N., and Calabretta B. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J. 16 (1997) 6151-6161
12. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., and Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 75 (1993) 817-825
13. Grignani F., Kinsella T., Mencarelli A., Valtieri M., Riganelli D., Grignani F., Lanfrancone L., Peschle C., Nolan G.P., and Pelicci P.G. High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein. Cancer Res. 58 (1998) 14-19
14. Nagahara H., Vocero-Akbani A.M., Snyder E.L., Ho A., Latham D.G., Lissy N.A., Becker-Hapak M., Ezhevsky S.A., and Dowdy S.F. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat. Med. 4 (1998) 1449-1452
15. Karlsson J., Edsjo A., Pahlman S., and Pettersson H.M. Multidrug-resistant neuroblastoma cells are responsive to arsenic trioxide at both normoxia and hypoxia. Mol. Cancer Ther. 4 (2005) 1128-1135
16. Nakamura Y., Ozaki T., Niizuma H., Ohira M., Kamijo T., and Nakagawara A. Functional characterization of a new p53 mutant generated by homozygous deletion in a neuroblastoma cell line. Biochem. Biophys. Res. Commun. 354 (2007) 892-898
17. Kaustov L., Lukin J., Lemak A., Duan S., Ho M., Doherty R., Penn L.Z., and Arrowsmith C.H. The conserved CPH domains of Cul7 and PARC are protein-protein interaction modules that bind the tetramerization domain of p53. J. Biol. Chem. 282 (2007) 11300-11307
18. Stommel J.M., Marchenko N.D., Jimenez G.S., Moll U.M., Hope T.J., and Wahl G.M. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J. 18 (1999) 1660-1672
19. Ostermeyer A.G., Runko E., Winkfield B., Ahn B., and Moll U.M. Cytoplasmically sequestered wild-type p53 protein in neuroblastoma is relocated to the nucleus by a C-terminal peptide. Proc. Natl. Acad. Sci. USA 93 (1996) 15190-15194
20. Iwakuma T., and Lozano G. MDM2, an introduction. Mol. Cancer Res. 1 (2003) 993-1000
21. Kalejta R.F., Shenk T., and Beavis A.J. Use of a membrane-localized green fluorescent protein allows simultaneous identification of transfected cells and cell cycle analysis by flow cytometry. Cytometry 29 (1997) 286-291